GH Research (GHRS) shares were soaring over 90% in Monday's premarket session after it said a phase 2b clinical trial of GH001 for patients with treatment-resistant depression met its primary endpoint.
The biopharmaceutical company also said all secondary endpoints were met and that GH001 was well tolerated with no serious adverse events reported in the double-blind part of the trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments